AUPH: Aurinia Pharmaceuticals Inc Price to Sales

Corporate company logo of Aurinia Pharmaceuticals Inc (AUPH)

Aurinia Pharmaceuticals (AUPH) maintains a pricing power advantage due to its first-mover status in lupus nephritis therapy with Lupkynis. The company's P/S ratio clearly demonstrates the market valuation of this asset, where 6.60 indicates the current level. The strategy is based on implementing an oral standard of care in immunology. Financial stability relies on strong liquidity, despite dependence on the pace of new patient acquisition.

Market Cap to Revenue: Aurinia Pharmaceuticals (AUPH) for 07/04/2022 - 11/16/2026

Analytical breakdowns for auriniapharma.com (AUPH)

- market capitalization information:
Fundamental company analysis:Aurinia Pharmaceuticals Inc. (AUPH)
Finished products of Aurinia Pharmaceuticals

Aurinia Pharmaceuticals (AUPH) ensures the supply of high-cost drugs for the therapy of autoimmune pathologies through a diversified network of international pharmacy hubs. By analyzing the P/S time series, an investor compares market capitalization with actual revenue, which allows for a real-time assessment of the business value relative to sales volume and determines whether the current price is undervalued or reflects hidden operational risks.

Competing companies

argenx - Market Cap to Revenue Ratio|P/S Multiple BNTX (biontech.de)|Abivax Corp (ABVX) - Price to Sales|ADMA Corp - P/S Multiple|Price-to-Sales Ratio PTGX|Immunovant Inc (IMVT) - Price-to-Revenue Ratio|KNSA - Price-to-Revenue Coefficient|GRFS (Grifols Biemat) - P/S Multiple|P/S Multiple Adaptive Biotechnologies Inc.|Price-to-Revenue Ratio Celldex Therapeutics (CLDX)|Market Cap to Revenue biocryst.com BCRX|Vera Therapeutics - Market Cap to Revenue|Market Cap to Sales Volume DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV - P/S Multiple|ABCL: Price-to-Revenue Ratio|Tourmaline Bio, Inc. (TRML) - Price-to-Revenue Ratio|Price to Sales precigen.com (PGEN)|PHAR (pharming.com) - P/S Multiple|NKTR (Nektar Therapeutics Inc.) - Market Cap to Sales Volume|P/S Multiple UPB|ZBIO - Price to Sales|P/S Multiple IMNM (immunome.com)|Gossamer Bio, Inc. - Price-to-Revenue Ratio|KalVista Pharmaceuticals, Inc. - P/S Multiple|SEPN (Septerna) - Market Cap to Revenue Ratio|Pieris Corp (PVLA) - Price-to-Revenue Ratio|SVRA - Price-to-Revenue Coefficient|RIGL (rigel.com) - P/S Multiple|Market Cap to Revenue Ratio ANAB (AnaptysBio, Inc.)|P/S Multiple ATXS|enGene Holdings Inc (ENGN) - Price-to-Revenue Multiple|P/S Multiple RAPT (RAPT Therapeutics Inc.)|JBIO (Aerovate) - Price-to-Sales Ratio|ACRS: Market Cap to Revenue|KYTX - P/S Multiple|TLSA: P/S Multiple|Market Cap to Revenue Cabaletta Bio, Inc|Price-to-Revenue Ratio Ventyx Biosciences, Inc|THTX: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue AVTX (Avalo Therapeutics, Inc)|Market Cap to Revenue Eledon Pharmaceuticals ELDN|Price-to-Revenue Ratio Agenus, Inc. AGEN|P/S Multiple Climb Bio Inc. CLYM|ZURA - Price-to-Revenue Ratio|Price-to-Sales Ratio ATYR|ADAG (Adagene Inc.) - Market Cap to Revenue|ImageneBio Inc (IMA) - P/S Multiple|Price-to-Revenue Ratio Shattuck Therapeutics|Market Cap to Revenue equilliumbio.com (EQ)|P/S Multiple CNTB|Price-to-Revenue Coefficient Immunic Therapeutics|P/S Multiple ATRA (Atara Biotherapeutics, Inc.)|IFRX - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio X4 Pharmaceuticals, Inc. (XFOR)|ACET (adicetbio.com) - Market Cap to Revenue Ratio|CELU: P/S Multiple|INMB - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Barinthus Biotherapeutics plc|KZR: Market Capitalization-to-Revenue Ratio|P/S Multiple SABS|AKTX (Akari Therapeutics Plc) - Market Capitalization-to-Revenue Ratio|P/S Multiple ENLV (Enlivex Therapeutics Ltd)|q32bio.com - Price-to-Revenue Ratio|GOVX: Market Cap to Revenue|edesabiotech.com (EDSA) - Market Cap to Revenue|IBIO: P/S Multiple|CARM - Price-to-Revenue Coefficient|Market Cap to Revenue XTLB|Market Cap to Revenue boltbio.com (BOLT)|Price-to-Revenue Ratio HCW Biologics Inc (HCWB)|P/S Multiple Aptevo Therapeutics, Inc. (APVO)|Price-to-Revenue Ratio aimimmuno.com AIM|Market Capitalization-to-Revenue Ratio ADTX|GRI Bio Corporation - P/S Multiple|XORTX Corp (XRTX) - Market Cap to Revenue|HIND (Vyome Holdings Inc.) - Market Cap to Revenue|revbiosciences.com (REVB) - P/S Multiple|INDP (Indaptus Corp) - P/S Multiple|Market Cap to Revenue Scinai Immunotherapeutics Ltd (SCNI)|Price-to-Revenue Ratio CalciMedica Inc (CALI)|AFMD (Affimed NV) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALLK (Allakos Inc.)|P/S Multiple HOOKIPA HOOK|IGMS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ITOS (iTeos)|OCEA: P/S Multiple|TCBP (TC BioPharm Ltd) - Price-to-Revenue Ratio|THRD (Third Harmonic Bio Inc) - P/S Multiple